Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran

LAUR Repository

Show simple item record

dc.contributor.author Kuyumjian, Yara
dc.contributor.author Miyares, Marta A.
dc.contributor.author Eaves, Shannon
dc.date.accessioned 2017-09-05T08:48:33Z
dc.date.available 2017-09-05T08:48:33Z
dc.date.copyright 2015 en_US
dc.date.issued 2017-09-05
dc.identifier.issn 1531-1937 en_US
dc.identifier.uri http://hdl.handle.net/10725/6127
dc.description.abstract Objective: To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent. Methods: A literature search was conducted consisting of a PubMed database using the MeSH term idarucizumab and the key word dabigatran antidote. Studies evaluating the pharmacology, pharmacokinetics, safety, and efficacy of idarucizumab for the reversal of the anticoagulant activity of dabigatran were included. Results: Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran. Studies evaluating reversal of dabigatran-induced anticoagulation have demonstrated immediate, complete, and sustained effects with idarucizumab. Idarucizumab did not overcorrect thrombin generation. Additionally, evaluations have shown that dabigatran can be safely reinitiated 24 hours after the administration of idarucizumab. The United States Food and Drug Administration granted priority review for the biologic license application and accelerated approval for idarucizumab. Conclusion: Idarucizumab represents an encouraging development in the reversal of dabigatran. Its novel mechanism of action, pharmacokinetics, tolerability, and lack of thrombotic events contribute positively to its use in patients who experience bleeding or for those who require emergent surgery or procedures. en_US
dc.language.iso en en_US
dc.title Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 200802837 en_US
dc.author.department Pharmacy Practice Department en_US
dc.description.embargo N/A en_US
dc.relation.journal Journal of Pharmacy Practice en_US
dc.journal.volume 28 en_US
dc.journal.issue 6 en_US
dc.article.pages 548-554 en_US
dc.keywords Anticoagulants en_US
dc.keywords Idarucizumab en_US
dc.keywords Dabigatran reversal en_US
dc.keywords Dabigatran antidote en_US
dc.identifier.doi http://dx.doi.org/10.1177/0897190015615248 en_US
dc.identifier.ctation Miyares, M. A., Kuyumjian, Y., Eaves, S., & Dollard, E. (2015). Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran. Journal of pharmacy practice, 28(6), 548-554. en_US
dc.author.email yara-mary.kouyoumdjian@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://journals.sagepub.com/doi/pdf/10.1177/0897190015615248 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account